Moreover, our results highlight the potential of targeting the Glo1/MG-H1/RAGE/H2O2/KRIT1 axis as a therapeutic strategy for aggressive PCa, particularly in tumors characterized by PI3K pathway hyperactivation and altered glycation signaling. This evidence concerns the gene KRIT1 and posterior cortical atrophy.